Clinical trialPhase 1Recruiting
Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors
A Phase I, Open-label, Single-arm, Dose-escalation and Expansion Study of Specific Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors
- Outcome
- Ongoing
- Cell product
- CAR-T cells
Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors
- Target antigen
- CLDN18.2
Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors
- Phase
- Phase 1
- Status
- Recruiting
- Study type
- Interventional
- Start
- 1 January 2024
- Listed end
- 30 October 2026
- Enrollment
- 29 participants
- Sites
- 1
- Primary outcomes
- Adverse Events (AEs); Dose-limiting toxicity (DLT); Recommended phase II dose (RP2D)
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 19 November 2024
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Claudin18.2(CLDN18.2) is a kind of integrin membrane protein in the tight junction between epithelium and endothelium, which is highly expressed in many solid tumors, especially in gastric cancer and pancreatic cancer. The CLDN18.2/PD-L1 dual-targeting CAR-T will be investigated in patients with CLDN18.2-positive advance solid tumors.
Detailed description public domain (ClinicalTrials.gov)
In this study, the CLDN18.2/PD-L1 dual-targeting CAR-T cells will be injected intravenously to patients with CLDN18.2-positive advanced solid tumors, such as gastric adenocarcinoma or gastroesophageal junction adenocarcinoma and pancreatic adenocarcinoma, who had nearly no response to standard treatment. The safety and effectiveness will be evaluated. The safety evaluation standard refers to the standard of CTCAE 5.0. The evaluation standard of effectiveness refers to the evaluation standard of solid tumor curative effect RECIST 1.1 to evaluate the curative effect. There are two phases of this study. The first is dose escalation phase, and 9 patients with CLDN18.2-positive advanced solid tumors are planned to be enrolled. The second is dose expansion phase. The curative effect has been observed in the first phase, and after the DLT observation period of the related dose group finished, the PI will decide whether to conduct the dose expansion research finally. It is planned to enroll 20 patients in dose expansion phase.
Intervention public domain (ClinicalTrials.gov)
Biological: Dual-targeting CLDN18.2 and PD-L1 CAR-T cells. The trial consists of a traditional '3 + 3' pattern dose-escalation phase and a dose-expansion phase.
Arm public domain (ClinicalTrials.gov)
CAR-T cell therapy (experimental): Dual-targeting CLDN18.2 and PD-L1 CAR-T cells